<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Introduction: Delayed facial palsy (DFP) is a common complication appearing ≥3 days after neurosurgery. In cases where glucocorticoids are contraindicated, other treatments are needed. Methods: The efficacy of BoNT-A injections was evaluated in patients with DFP after vestibular schwannoma resection. Patients received: Group I, BoNT-A (40–50 IU); Group II, prednisolone (1 mg/kg per day, 5–7 days); Group III, glucocorticoids with BoNT-A; Group IV, refused treatment. Functional efficacy was assessed. Results: Among 75 patients, pretreatment facial nerve dysfunction was mild, moderate, and moderate-to-severe in 48.0%, 33.3%, and 18.7%, respectively. One month post-treatment initiation, Group III had a significantly higher rate of facial symmetry normalization versus Groups II and IV (P &lt; 0.05). After 3 months, complete recovery of facial nerve function was significantly higher in Groups I–III versus Group IV (P &lt; 0.05). Conclusion: BoNT-A injections may be recommended for DFP treatment to attenuate facial asymmetry and improve functional recovery.</p>
</abstract>

Introduction: Delayed facial palsy (DFP) is a common complication appearing ≥3 days after neurosurgery. In cases where glucocorticoids are contraindicated, other treatments are needed. Methods: The efficacy of BoNT-A injections was evaluated in patients with DFP after vestibular schwannoma resection. Patients received: Group I, BoNT-A (40–50 IU); Group II, prednisolone (1 mg/kg per day, 5–7 days); Group III, glucocorticoids with BoNT-A; Group IV, refused treatment. Functional efficacy was assessed. Results: Among 75 patients, pretreatment facial nerve dysfunction was mild, moderate, and moderate-to-severe in 48.0%, 33.3%, and 18.7%, respectively. One month post-treatment initiation, Group III had a significantly higher rate of facial symmetry normalization versus Groups II and IV (P < 0.05). After 3 months, complete recovery of facial nerve function was significantly higher in Groups I–III versus Group IV (P < 0.05). Conclusion: BoNT-A injections may be recommended for DFP treatment to attenuate facial asymmetry and improve functional recovery.

Botulinum Toxin a Treatment of Delayed Facial Palsy in a Randomized Trial

I.M. Sechenov First Moscow State Medical University

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Botulinum Toxin a Treatment of Delayed Facial Palsy in a Randomized Trial"}

Introduction: Delayed facial palsy (DFP) is a common complication appearing ≥3 days after neurosurgery. In cases where glucocorticoids are contraindicated,...

Botulinum Toxin a Treatment of Delayed Facial Palsy in a Randomized Trial

Published Online: Aug 05, 2021

Page range: 137 - 144

Received: Nov 13, 2020

Accepted: Dec 08, 2020

DOI: https://doi.org/10.2478/sjecr-2020-0063

Keywords
delayed facial palsy, botulinum toxin type A, house–brackmann scale, rehabilitation

© 2021 Mikhail A. Akulov et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Botulinum Toxin a Treatment of Delayed Facial Palsy in a Randomized Trial

Published Online: Aug 05, 2021

Page range: 137 - 144

Received: Nov 13, 2020

Accepted: Dec 08, 2020

DOI: https://doi.org/10.2478/sjecr-2020-0063

Keywordsdelayed facial palsy, botulinum toxin type A, house–brackmann scale, rehabilitation

© 2021 Mikhail A. Akulov et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Keywords
delayed facial palsy, botulinum toxin type A, house–brackmann scale, rehabilitation